



ASX / MEDIA RELEASE

17<sup>th</sup> February 2017

## Granted Reimbursement for Refractory mCRC in France

**Sydney, Australia; 17<sup>th</sup> February 2017** – Sirtex Medical Limited (ASX:SRX) is pleased to announce that the French Ministry of Health, Ministère des Affaires sociales et de la Santé, has agreed to reimburse Selective Internal Radiation Therapy (SIRT) with SIR-Spheres<sup>®</sup> Y-90 resin microspheres for patients with colorectal liver metastases who have failed on or are intolerant to prior chemotherapy. The Ministry based its decision on clinical evidence of the efficacy and safety of SIR-Spheres<sup>®</sup> Y-90 resin microspheres for treating this patient population, and has agreed to provide reimbursement commencing in the first quarter of this year.

Mr Nigel Lange, Interim Chief Executive Officer of Sirtex Medical Limited said “The granting of reimbursement in France is specific to SIR-Spheres Y-90 resin microspheres in refractory metastatic colorectal cancer, and highlights the accepted evidence of clinical benefit for patients who have had their cancer progress despite systemic chemotherapy treatments. Awareness of and expertise in the use of our product has grown significantly in France following the SARAH clinical study of 460 patients with advanced, inoperable primary liver cancer, who were treated at 25 specialised centres.”

Reimbursement in France is specific to SIR-Spheres Y-90 resin microspheres and recognises the innovative and specific product characteristics of this trademarked product.

Mr Lange further commented “With reimbursement now secured in France, we anticipate an increasing contribution of our EMEA dose sales mix to originate from this important market over the coming years.”

The estimated annual incidence of colorectal cancer in France was approximately 41,000 cases in 2012; it is also the country’s third most common cause of cancer mortality, accounting for approximately 17,000 deaths each year<sup>1</sup>. The French healthcare system is a universal healthcare model and is government managed. Over 95% of the population have health insurance under four main insurance schemes.

### About Colorectal Cancer

Colorectal cancer (CRC or bowel cancer) occurs when cancerous cells develop in the patient’s colon or rectum. CRC is the third most common form of cancer worldwide, making up about 10% of all cancers. In 2012, an estimated 1.4 million new cases were diagnosed globally and 694,000 cancer deaths were attributed to CRC.<sup>2</sup>

---

**Head Office**  
Level 33, 101 Miller Street  
North Sydney, NSW 2060  
Australia

**Americas**  
300 Unicorn Park Drive  
Woburn, MA 01801  
United States

**Europe, Middle East & Africa**  
Josef-Schumpeter-Allee 33  
53227 Bonn  
Germany

**Asia Pacific**  
50 Science Park Road, #01-01  
The Kendall Science Park II  
Singapore 117406

## About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

## About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit [www.sirtex.com](http://www.sirtex.com).

For further information please contact:

### Investor Enquiries:

Mr Nigel Lange  
Interim CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

### Investor/Media Enquiries:

Dr Tom Duthy  
Global Investor Relations Manager  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

---

<sup>1</sup> Ferlay J *et al.* GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on 17/11/2016.

<sup>2</sup> World Cancer Report, 2014; Geneva, WHO: 2014; 1.1.